Evidence map›Paper›PMID 34189383›Full record

ArticleJBMR plus2021

Ten-Year Simulation of the Effects of Denosumab on Bone Remodeling in Human Biopsies.

Duncan C Tourolle, David W Dempster, Charles Ledoux, Daniele Boaretti, Mauricio Aguilera, Najma Saleem, Ralph Müller

Open access · goldAbstract read
In one paragraph

Article in JBMR plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Clinical Data for Parametrization ofFrontiers in bioengineering and biotechnology · 2022
    Pooled it
  2. Review
  3. The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Observational
  4. Article
  5. Article
  6. Review
  7. AnFrontiers in bioengineering and biotechnology · 2023
    Article
  8. Article
  9. Trabecular bone remodeling in the aging mouse: A micro-multiphysics agent-basedFrontiers in bioengineering and biotechnology · 2023
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Duncan C TourolleInstitute for Biomechanics ETH Zurich Zurich Switzerland.
David W DempsterDepartment of Pathology and Cell Biology College of Physicians and Surgeons of Columbia University New York NY USA.ORCID https://orcid.org/0000-0002-2262-4039
Charles LedouxInstitute for Biomechanics ETH Zurich Zurich Switzerland.ORCID https://orcid.org/0000-0002-0344-1608
Daniele BoarettiInstitute for Biomechanics ETH Zurich Zurich Switzerland.ORCID https://orcid.org/0000-0001-8411-7465
Mauricio AguileraAmgen Inc Mexico City Mexico.
Najma SaleemAmgen Inc Thousand Oaks CA USA.
Ralph MüllerInstitute for Biomechanics ETH Zurich Zurich Switzerland.ORCID https://orcid.org/0000-0002-5811-7725
ETH Zurich · CHAmgen (United States) · USColumbia University · USMSD (Mexico) · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postmenopausal osteoporosis is a disease manifesting in degradation of bone mass and microarchitecture, leading to weakening and increased risk of fracture. Clinical trials are an essential tool for evaluating new treatments and may provide further mechanistic understanding of their effects in vivo. However, the histomorphometry from clinical trials is limited to 2D images and reflects single time points. Biochemical markers of bone turnover give global insight into a drug's action, but not the local dynamics of the bone remodeling process and the cells involved. Additionally, comparative trials necessitate separate treatment groups, meaning only aggregated measures can be compared. In this study, in silico modeling based on histomorphometry and pharmacokinetic data was used to assess the effects of treatment versus control on μCT scans of the same biopsy samples over time, matching the changes in bone volume fraction observed in biopsies from denosumab and placebo groups through year 10 of the FREEDOM Extension trial. In the simulation, treatment decreased osteoclast number, which led to a modest increase in trabecular thickness and osteocyte stress shielding. Long-term bone turnover suppression led to increased RANKL production, followed by a small increase in osteoclast number at the end of the 6-month-dosing interval, especially at the end of the Extension study. Lack of treatment led to a significant loss of bone mass and structure. The study's results show how in silico models can generate predictions of denosumab cellular action over a 10-year period, matching static and dynamic morphometric measures assessed in clinical biopsies. The use of in silico models with clinical trial data can be a method to gain further insight into fundamental bone biology and how treatments can perturb this. With rigorous validation, such models could be used for informing the design of clinical trials, such that the number of participants could be reduced to a minimum to show efficacy. © 2021 The Authors.

Indexed as

BONE HISTOMORPHOMETRYBONE REMODELINGOSTEOPOROSISSIMULATIONTHERAPEUTICS

Identifiers

PMID34189383
PMCPMC8216138
OpenAlexW3136945091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.